摘要
目的:探讨CK20及Cjun在膀胱癌中的表达和临床意义。方法:应用免疫组化SABC法检测52 例膀胱癌组织及10例正常人膀胱组织中的CK20 及Cjun 的表达。结果:52 例膀胱癌组织中48 例(92.3%)CK20阳性表达,47例(90.38%)Cjun阳性表达, 正常对照组织分别为1例(10.0%)和0例,正常对照组织与膀胱肿瘤间CK20和Cjun表达差异有统计学意义(分别为P<0.01、P<0.01);但是CK20及Cjun的表达与肿瘤分期分级及预后无明显相关。结论:CK20及Cjun在肿瘤组织中表达明显增高,但与分期分级无关。
Objective:We examined the presence of CK20 and Cjun, as detected by immunohistochemistry, and correlated with the classic variables (grade, stage and recurrence).Methods:The authors evaluated 52 bladder transitional cell carcinomas and 10 controls, Association of CK20 and Cjun immunoreactivity with tumor grade, clinical stage and tumor recurrence was examined.Results:Expression of CK20 was founded in 92.31% of TCCs and Cjun was 90.38%(P< 0.01, P< 0.01), but CK20 and Cjun were not correlated with grade, stage and recurrence of the disease.Conclusions:CK20 and Cjun expression increase dramatically in TCC, but have no relationship with grade of the disease. Neither of them can be the predictors of tumor recurrence for patients with bladder transitional cell carcinoma.
出处
《临床泌尿外科杂志》
2005年第5期288-290,共3页
Journal of Clinical Urology
